Intramyocardial Implantation of CD133<sup>+</sup> Stem Cells Improved Cardiac Function without Bypass Surgery
DOI:
https://doi.org/10.1532/HSF98.20061054Abstract
Introduction. Cell transplantation for myocardial regeneration has been shown to have beneficial effects on cardiac function after myocardial infarction. Most clinical studies of intramyocardial cell transplantation were performed in combination with coronary artery bypass grafting (CABG). The contribution of implanted stem cells could yet not be clearly distinguished from the effect of the CABG surgery. Our current phase 1 clinical study has focused on the safety and feasibility of CD133+-enriched stem cell transplantation without CABG and its potential beneficial effect on cardiac function.
Method and Results. Ten patients with end-stage chronic ischemic cardiomyopathy (ejection fraction <22%) were enrolled in the study. Bone marrow (up to 380 mL) was harvested from the iliac crest. CD133+ cells were purified from bone marrow cells using the CliniMACS device with purities up to 99%. Autologous bone marrow CD133+ cells (1.5-9.7 X 106 cells) were injected into predefined regions. Cardiac functions prior to and 3, 6, and 9 months after cell transplantation were assessed by cardiac magnetic resonance imaging. Stem cell transplantation typically improved the heart function stage from New York Heart Association/Canadian Cardiovascular Society class III-IV to I-II. The mean preoperative and postoperative ventricular ejection fractions were 15.8 ± 5% and 24.8 ± 5%, respectively.
Conclusion. CD133+ injection into ischemic myocardium was feasible and safe. Stem cell transplantation alone improved cardiac function in all patients. This technique might hold promise as an alternative to medical management in patients with severe ischemic heart failure who are ineligible for conventional revascularization.
References
Assmus B, Schachinger V, Teupe C, et al. 2002. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106:3009-17.nFuchs S, Baffour R, Zhou YF, et al. 2001. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 3:1726-32.nGhodsizad A, Klein HM, Borowski A, et al. 2004. Intraoperative isolation and processing of BM-derived stem cells. Cytotherapy 6:523-6.nGhodsizad A, Ruhparwar A, Marktanner R, et al. 2006. Autologous transplantation of CD133+ BM-derived stem cells as a therapeutic option for dilatative cardiomyopathy. Cytotherapy 8:308-10.nHamano K, Nishida M, Hirata K, et al. 2001. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. Jpn Circ J 65:845-7.nKawamoto A, Gwon HC, Iwaguro H, et al. 2001. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103:634-7.nKocher AA, Schuster MD, Szabolcs MJ, et al. 2001. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7:430-6.nKlein HM, Ghodsizad A, Borowski A, et al. 2004. Autologous bone marrow-derived stem cell therapy in combination with TMLR. A novel therapeutic option for endstage coronary heart disease: report on 2 cases. Heart Surg Forum 7:E416-9.nOrlic D, Kajstura J, Chimenti S, et al. 2001. Bone marrow cells regenerate infarcted myocardium. Nature 410:701-5.nPerin EC, Dohmann HF, Borojevic R, et al. 2004. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 110:213-8.nPesce M, Orlandi A, Iachininoto MG, et al. 2003. Myoendothelial differentiation of human umbilical cord blood-derived stem cells in ischemic limb tissues. Circ Res 93:51-62.nPompilio G, Cannata A, Peccatori F, et al. 2005. Autologous peripheral blood stem cell transplantation for myocardial regeneration: a novel strategy for cell collection and surgical injection. Ann Thorac Surg 78:1808-12.nSilva GV, Perin EC, Dohmann HF, et al. 2004. Catheter-based transendocardial delivery of autologous bone marrow-derived mono-nuclear cells in patients listed for heart transplantation. Tex Heart Inst J 31:214-9.nStamm C, Westphal B, Kleine HD, et al. 2003. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361:45-6.nStrauer BE, Brehm M, Zeus T, et al. 2002. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106:1913-8.nTang GH, Fedak PW, Yau TM, et al. 2003. Cell transplantation to improve ventricular function in the failing heart. Eur J Cardiothorac Surg 23:907-16.nToma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. 2002. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105:93-8.nTomita S, Li RK, Weisel RD, et al. 1999. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 100:247-56.n
